Search

Objective: To study the molecular mechanism of celery seed inhibiting or treating gout by using network pharmacology and molecular docking. Methods: TCMSP database and the network maps were constructed with Cytoscape3.9.0 software. Gout-related targets were collected in GeneCard database and OMIM database, crossed with the main component targets of celery seed and imported into STRING database for protein-protein interaction （protein-protein interaction, PPI） analysis, core targets were obtained, core targets were introduced into DAVID, and GO function enrichment and KEGG pathway enrichment were performed in the database. Finally, AutoDock software was used to verify the key components with key targets. Results: There were 16 main components of celery seeds, 69 common targets. After topological analysis, quercetin, apigenin, luteolin, celery, five core components and 10 key targets of gout TNF, MAPK14, IL4, CXCL8, LYN, PDGFRβ, HCK, VEGFA, ITGA, IL2, were closely involved in inhibiting or treating gout. The results of GO and KEGG analysis showed that the core components of celery seed acted through regulating biological processes such as apoptosis, proliferation and migration, and through PI3K-Akt signaling pathway, IL-17 signaling pathway, MAPK signaling pathway, and NF-κB signaling pathway. The molecular docking results showed that the five core components were closely bound to the 10 key target proteins with high confidence, verifying the accuracy of the network pharmacology prediction results. Conclusion: This study reveals the role of celery seed in inhibiting or treating gout, and lays a foundation for the development of single Chinese herbal medicine and the study of "medicine and food homology" to control metabolic diseases.

Background Long-acting antipsychotics are currently important therapeutic options for the long-term treatment of schizophrenia. Risperidone microspheres for injection (Ⅱ) has been modified in dosage form to ensure fast acting without oral antipsychotic supplementation during treatment, however, there is a lack of studies on the efficacy and safety of it. Objective To evaluate the efficacy and safety of risperidone microspheres for injection (Ⅱ) in patients with acute schizophrenia. Methods This is a single-arm multicenter prospective study. The patients aged 18-55 years with acute schizophrenia from August 2021 to April 2022 at five study centers including Peking University Sixth Hospital, Hebei Provincial Mental Health Center, the Fourth People's Hospital in Urumqi, Taiyuan Psychiatric Hospital and Tianjin Anding Hospital were included and given variable dose of risperidone microspheres for injection (Ⅱ) of 25.0 mg/2 weeks, 37.5 mg/2 weeks or 50.0 mg/2 weeks and followed up for 8 weeks. The Positive and Negative Symptom Scale (PANSS), Clinical Global Impression Scale (CGI-S) and the Udvalg for Kliniske Undersogelser (UKU) Side Effects Rating Scale were used for evaluation at baseline and the end of week 2, 4, 6 and 8. In addition, Personal and Social Performance (PSP) Scale were evaluated and laboratory tests were collected at baseline and the end of week 8. Results A total of 58 patients were included in the study. PANSS total score, PANSS-positive score, PANSS-negative score, PANSS-general psychopathology score and CGI-S score were significantly reduced at the end of week 2, 4, 6 and 8 compared to baseline (P